Already inside the gate: the company is specified into someone else's next wave, and the wave has not yet shipped
The model's full reasoning — Q3 2023 call → NOWe need to determine if the transcript describes a situation where the company (Novavax) has already been chosen, specified, qualified, designed into another organization's future product/program/platform, and that the wave (volume/revenue) has not yet arrived, and the position is large relative to the company. Let's analyze the transcript. The key topics: COVID vaccine launch, combination COVID-flu vaccine, Matrix-M adjuvant partnerships, APAs (advance purchase agreements) with governments. The question asks about "another organization's future product, program, platform, build-out, or standard operating plan" - meaning a counterparty's next thing. For Novavax, the most relevant is the combination COVID-flu vaccine? But that's their own product. The Matrix-M adjuvant is used in other companies' vaccines? The transcript mentions: "It's included in veterinary vaccines commercialized by MSD Animal Health and Intervacc in Europe with additional vaccines in development. It's included in the R21 malaria vaccine that has recently received WHO SAGE Recommendations for use. As we have previously announced, it's in preclinical evaluation by The Bill & Melinda Gates Medical Research Institute for Targets of Public Health Importance and in addition to its use in our own pipeline products. It is being evaluated as a component in 12 clinical stage candidates by biotech, academic, and government partners. And finally, it's being evaluated in animal models by a biopharma partner to improve currently authorized vaccines against herpes and respiratory viruses." So Matrix-M is used in other parties' products. But is that a "secured position" where the wave hasn't arrived? The R21 malaria vaccine has received WHO SAGE recommendation, but is it launched? The transcript says "as our partner Serum is preparing to launch as early as next year" - so that's a future wave. But is that a large position relative to Novavax? The revenue from Matrix-M royalties might be small. The transcript mentions $12 million Matrix R21 revenue this quarter. That's not huge. The main focus is on the COVID vaccine and the combination vaccine. The combination vaccine is their own product, not another organization's. The APAs are with governments - those are purchase orders, but they are committed.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NC | NACCO Industries, Inc. | Q1 2024 | 2024-05-05 | C+ |
| CLGN | CollPlant Biotechnologies Ltd. | Q4 2023 | 2024-04-04 | F |
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| AIRG | Airgain, Inc. | Q3 2023 | 2023-11-09 | F |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| THRM | Gentherm Incorporated | Q2 2016 | 2016-07-28 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| SPR | Spirit AeroSystems Holdings, Inc. | Q1 2016 | 2016-04-29 | D |
CUBI · Q3 2018 → YESThe question is about whether management describes that the company has already been chosen or locked into another organization's future product/program, such that volume will come automatically when ...NO The transcript describes a white-label partnership with T-Mobile where BankMobile provides services under T-Mobile's brand, with deposits expected to start in the next year after the launch. However, this does not meet the criteria for a secured position inside T-Mobile's next product or program. The language focuses on a partnership relationship that is still being launched, rather than a design win or qualification already embedded in T-Mobile's future offering. Management refers to it as an "expected white label partnership" and "working on" the launch, indicating it is not yet locked in as part of T-Mobile's committed plan.
EMKR · Q4 2023 → YESThe question is about whether management describes that the company has already been chosen or locked into another organization's future product/program, such that volume will come automatically when ...NO The transcript describes an agreement with Kratos for Inertial Navigation Systems to be included in the XQ58 Valkyrie drone, with the Air Force planning to acquire at least 1,000 units. However, this is framed as an announcement of a new agreement rather than a secured, locked-in position already designed 100% into the platform with volume guaranteed.
NC · Q1 2024 → YESThe question is about whether management describes that the company has already been chosen or locked into another organization's future product/program, such that volume will arrive automatically whe...